Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells

BACKGROUND: Aberrant expression of Secretory Leukocyte Protease Inhibitor (SLPI) has been associated with human cancer growth and its suppression was identified as a potential target for anti-cancer drugs, particularly in colorectal cancer. However, the underlying mechanism by which SLPI affected th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Zhijiang, Liu, Guiying, Jia, Rufu, Zhang, Wei, Li, Li, Zhang, Yuanyuan, Wang, Zhijing, Bai, Xiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810770/
https://www.ncbi.nlm.nih.gov/pubmed/36595102
http://dx.doi.org/10.1007/s12672-022-00535-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810770/
https://www.ncbi.nlm.nih.gov/pubmed/36595102
http://dx.doi.org/10.1007/s12672-022-00535-9

Ejemplares similares